Literature DB >> 21909455

Management of Papulopustular Rosacea and Perioral Dermatitis with Emphasis on Iatrogenic Causation or Exacerbation of Inflammatory Facial Dermatoses: Use of Doxycycline-modified Release 40mg Capsule Once Daily in Combination with Properly Selected Skin Care as an Effective Therapeutic Approach.

James Q Del Rosso1.   

Abstract

A variety of inflammatory facial dermatoses, such as papulopustular rosacea and perioral dermatitis, are often idiopathic. However, prolonged continuous and/or repeated intermittent topical corticosteroid use can exacerbate these disorders or, in some cases, induce them. This article discusses corticosteroid-induced rosacea-like dermatitis and primary perioral dermatitis with regard to clinical presentations, including in both adults and children, and management considerations. The rationale for use of an anti-inflammatory dose of doxycycline that is subantimicrobial, doxycycline modified-release 40mg capsule once daily, along with properly selected skin care, is discussed. Case illustrations are also included.

Entities:  

Year:  2011        PMID: 21909455      PMCID: PMC3168247     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  39 in total

1.  Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis.

Authors:  T Dirschka; H Tronnier; R Fölster-Holst
Journal:  Br J Dermatol       Date:  2004-06       Impact factor: 9.302

2.  Eyelid dermatitis to red face syndrome to cure: clinical experience in 100 cases.

Authors:  M J Rapaport; V Rapaport
Journal:  J Am Acad Dermatol       Date:  1999-09       Impact factor: 11.527

3.  Adverse effect of topical fluorinated corticosteroids in rosacea.

Authors:  I Sneddon
Journal:  Br Med J       Date:  1969-03-15

4.  Steroid rosacea.

Authors:  J J Leyden; M Thew; A M Kligman
Journal:  Arch Dermatol       Date:  1974-10

5.  Topical calcitriol restores the impairment of epidermal permeability and antimicrobial barriers induced by corticosteroids.

Authors:  S P Hong; Y Oh; M Jung; S Lee; H Jeon; M-Y Cho; S H Lee; E H Choi
Journal:  Br J Dermatol       Date:  2010-03-10       Impact factor: 9.302

6.  Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities.

Authors:  Jack S Kao; Joachim W Fluhr; Mao-Qiang Man; Ashley J Fowler; Jean-Pierre Hachem; Debra Crumrine; Sung K Ahn; Barbara E Brown; Peter M Elias; Kenneth R Feingold
Journal:  J Invest Dermatol       Date:  2003-03       Impact factor: 8.551

Review 7.  Steroid-induced rosacealike dermatitis: case report and review of the literature.

Authors:  Amy Y-Y Chen; Matthew J Zirwas
Journal:  Cutis       Date:  2009-04

Review 8.  Role of mild cleansing in the management of patient skin.

Authors:  Kumar Subramanyan
Journal:  Dermatol Ther       Date:  2004       Impact factor: 2.851

9.  Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea.

Authors:  James Q Del Rosso; Guy F Webster; Mark Jackson; Marta Rendon; Phoebe Rich; Helen Torok; Mark Bradshaw
Journal:  J Am Acad Dermatol       Date:  2007-03-23       Impact factor: 11.527

10.  Anti-inflamatory dose doxycycline in the treatment of rosacea.

Authors:  James Q Del Rosso
Journal:  J Drugs Dermatol       Date:  2009-07       Impact factor: 2.114

View more
  2 in total

1.  Subantimicrobial-dose doxycycline monohydrate in dermatology.

Authors:  Uwe Wollina
Journal:  Wien Med Wochenschr       Date:  2015-11-13

2.  Doxycycline attenuates breast cancer related inflammation by decreasing plasma lysophosphatidate concentrations and inhibiting NF-κB activation.

Authors:  Xiaoyun Tang; Xianyan Wang; Yuan Y Zhao; Jonathan M Curtis; David N Brindley
Journal:  Mol Cancer       Date:  2017-02-08       Impact factor: 27.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.